semaglutide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42478869
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
- 저자
- Silvio E Inzucchi, Rohana Abdul Ghani, John Deanfield, Scott Emerson, Mads D M Engelmann, G Kees Hovingh
- 저널
- The Journal of clinical endocrinology and metabolism
- 공개일
- 2026 Jul 21
- 연구 유형
- 기타
- DOI
- 10.1210/clinem/dgag290
문헌 요약
In the SOUL trial (NCT03914326), oral semaglutide reduced risk of major adverse cardiovascular (CV) events (MACE) by 14%. Whether baseline or changes in HbA1c or BMI are associated with these CV benefits is not known. We evaluated whether CV benefits of oral semaglutide are associated with baseline or in-trial reductions in HbA1c or BMI. Post hoc analysis…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.